# **Data Mining Techniques for Iraqi Biochemical Dataset Analysis**

#### Sarah Sameer\*

Suhad Faisal Behadili

Computer Science Department, College of Science, University of Baghdad, Baghdad, Iraq. \*Corresponding author: <u>sarahsameer@scbaghdad.edu.iq</u>\*, <u>suhad.f@sc.uobaghdad.edu.iq</u> \*ORCID ID: https://orcid.org/0000-0002-6897-2864\*, https://orcid.org/0000-0003-4617-8464 +9647702583537

Received 13/7/2020, Accepted 19/1/2021, Published Online First 20/9/2021, Published 1/4/2022



This work is licensed under a <u>Creative Commons Attribution 4.0 International License</u>.

#### Abstract:

This research aims to analyze and simulate biochemical real test data for uncovering the relationships among the tests, and how each of them impacts others. The data were acquired from Iraqi private biochemical laboratory. However, these data have many dimensions with a high rate of null values, and big patient numbers. Then, several experiments have been applied on these data beginning with unsupervised techniques such as hierarchical clustering, and k-means, but the results were not clear. Then the preprocessing step performed, to make the dataset analyzable by supervised techniques such as Linear Discriminant Analysis (LDA), Classification And Regression Tree (CART), Logistic Regression (LR), K-Nearest Neighbor (K-NN), Naïve Bays (NB), and Support Vector Machine (SVM) techniques. CART gives clear results with high accuracy between the six supervised algorithms. It is worth noting that the preprocessing steps take remarkable efforts to handle this type of data, since its pure data set has so many null values of a ratio 94.8%, then it becomes 0% after achieving the preprocessing steps. Then, in order to apply CART algorithm, several determined tests were assumed as classes. The decision to select the tests which had been assumed as classes were depending on their acquired accuracy. Consequently, enabling the physicians to trace and connect the tests result with each other, which extends its impact on patients' health.

**Keywords:** Biomedical, Classification And Regression Tree (CART), Data mining, Hierarchical clustering, K-means.

### **Introduction:**

The biochemical tests make a wide correlation with human organs functions, as well as the imbalanced glands and hormones. Therefore, they help in discovering the diseases and future risks. The used tests types are include, blood tests that are related to chronic diseases and include lipid, liver function, renal function, carbohydrates, bone markers, electrolytes, anemia, pancreatic function, coagulation, and cardiac function tests. Likewise, the previous researches that have used biochemical tests have diagnosed breast cancer, diabetes, and heart diseases for several specific tests such as in <sup>1-3</sup>. While in this paper, the dataset have more biochemical tests over the previous works, also there is no specified disease diagnosed. Data mining (DM) as an important science in the biomedical analysis domain, it participates to discover hidden knowledge and rules from the dataset by extracting patterns, clusters, or relationships <sup>4-5</sup>. The big challenge in this search is the null values ratio, and how to cover this issue by proposing algorithm to

solve it. Also, the assumption classes were necessary for work with supervised algorithms, then classify data in order to analysis tests to discover patterns of relationships. The remainder of this paper is organized as follows, section 2 presents related work, section 3 presents methodology, section 4 presents data mining techniques, 5 presents CART algorithm, 6 present model implementation, and lastly discussions and conclusions.

### **Related Work**

There are many researches addressed various issues of DM approaches. Hence, in <sup>1</sup> they apply machine learning algorithms (J48, simple logistic, and Multiplayer Perceptions (MLP)) using Weka DM tools, they observe real data that are acquired from several Iraqi hospitals of early detection for breast cancer. The researchers also applied 10 - folds cross - validation as a test option and a confusion matrix as a performance

metric to choose the optimal one from proposed algorithms. Also, the error ratio was tested, which decreased after 5-10 iterations of algorithm execution in the case of MLP algorithm rather than simple logistic, and J48 algorithms. While in  $^{2}$ , the Pima Indian Diabetes dataset was used to improve the system accuracy for classifying diabetes disease. The researchers proposed a hybrid of machine learning algorithms, Self-Organizing Map (SOM), Principal Component Analysis (PCA), and neural network (NN) for clustering, noise removal, and classification tasks respectively. Whereas in <sup>3</sup>, The diabetic patients' information from Ulster Community and Hospitals Trust (UCHT) for the years 2000 to 2004, which are used to predict how well the patients' condition was controlled. The researchers used feature selection via supervised model construction (FSSMC) and optimization of ReliefF to decide the important parameters in diabetic control, then the classification techniques Naive Bayes (NB), IB1, and decision tree C4.5 were applied to the data. In <sup>4</sup> they used two benchmark medical datasets from the UCML repository to find risk patterns. They proposed Mining Optimal Risk pattern sets (MORE) algorithm for risk patterns extraction. So, they compared the proposed method with the decision tree C5.0 algorithm, a commercial version of C4.5, association rule mining-based and variant approaches (Apriori). However, in <sup>6</sup> the dataset is collected from the Ministry of Health, Saudi Arabia. It supports vector machine algorithms that were applied to investigate which treatment case is more efficient for each age category of diabetes patients. The researchers used the Oracle Data Miner tool to analyze their data. As well as, in <sup>7</sup> the used data of Multiparameter Intelligent Monitoring Intensive Care II (MIMIC-II) physiology patients are investigated via DM techniques, logistic regression, NN, DT, and K-Nearest Neighbor for predicting death cases within the next 24 hours. So, NN and logistic regression generated better results, while the configuring parameters contributed to model success. In turn, the researchers of <sup>8</sup> have been experimenting disease prediction tools from eight different predictive classifiers. These classifiers are NB, decision tree J48, Instance-Based Learning (IBK), Sequential Minimum Optimization (SMO), MLP, DT Reduced Error Pruning (REP) Tree, Projective Adaptive Resonance Theory (PART), and Random Forest (RF). They used data for breast cancer, diabetes, heart disease, Tuberculosis (TB), and liver disorder available from UCI, and another source of data contains Human that Immunodeficiency Virus (HIV). These data sets are gathered from Amana hospital in Dares-salaam,

Tanzania. They developed two-hybrid systems, the first one used Wisconsin Breast Cancer dataset with combinations of SMO+RF+IBK, and SMO+RF+MLP. which introduced good performance. Whereas, in the second one they used an HIV dataset with a combination of SMO + J48 + MLP that exhibited good performance. Indeed, the 10 - fold cross - validation was used as a test option, while the confusion matrix as a performance metric. Furthermore, in <sup>9</sup> the used dataset is acquired via a general hygiene questionnaire form, which was designed and distributed for 200 students of two high schools in Baghdad city. The questions reflect general environmental health characteristics. The proposed approach consists of three DM techniques, Apriori, association rule mining, and NB respectively. They encoded and analyzed the data using the Weka DM tool for uncovering hidden relationships among their parameters.

This research use real mixture data, from private laboratory, which consist of many blood tests that no predecessor research has analyzed. While the past researches usually used part of those tests to diagnostic specific disease. Noticed from the previous works, that supervised techniques useful for such type of data.

# Material and Methods: Material:

In this study, the relationship between real biochemical tests have been analyzed to help in discovering how they affect each other, in order to help in reduce the tests number, as well as the tests cost. Raw data have been used, there are no research have used same of our dataset, also we have proposed powerful preprocessing and DM algorithms for such type of dataset. The investigated data have been manipulated through many experiments to discover the relationship between the tests, and the affected patterns on the class value. The shape of the data has clearly affected the steps of preprocessing type. In the next section, some issues will be addressed like the data description, experiments that have been applied, and the results of each experiment.

# Data Description

The investigated dataset was borrowed from a private Iraqi laboratory in Baghdad city, and recorded as a handwritten hard copy, then it had been converted to an electronic copy. The patients' cases had been described by 71 parameters. Whereas, the parameters had been classified into two groups. The first group consists of 66 parameters that present chemical tests, while the second group consists of 5 parameters that present personal information such as patient name, which already exists in the raw dataset. However, the index, gender, age, and date have been added during preprocessing steps. Moreover, the patients' number is 5609. However, the females' number is 2691, while the males' number is 2918. Nevertheless, the adult number is 5461, and the children number is 148. The tests details had been gained by interviewing a laboratory physician, also by the recorded documents and laboratory guidelines. The data could be described as in Table 1.

r.	<b>Fable1. Biomedical</b>	data desc	ription with r	iorma	l values.
	E. 11	D		1	• •

$ \begin{array}{ c c c c c } Int64 & patient unique number \\ Name object patient gender dobject patient gender \\ Age object patient gender \\ Age object est date \\ \hline \begin{tabular}{l c c c c } Ch & Int64 & Cholesterol, serum \\ Int64 & Cholesterol, serum \\ Int64 & Triglyceride, serum, mg/dL & Male \\ 60 - 160 & 40 - 140 \\ Int64 & Int64 & Int64 & Cholesterol, serum \\ Int64 & In$	Field name	Data type	description		normal valu	ue	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			*				
$ \begin{array}{c c c c c } Gender & object & patient gender & M \cdot F \\ Age & object & patient age & child - adult \\ \hline \begin{timessample}{c c c c c c } \hline \begin{timessample}{c c c c c c } \hline \begin{timessample}{c c c c c } \hline \begin{timessample}{c c c c c } \hline \begin{timessample}{c c c c c c } \hline \begin{timessample}{c c c c c } \hline \begin{timessample}{c c c c c } \hline \begin{timessample}{c c c c c c } \hline \begin{timessample}{c c c c c c } \hline \begin{timessample}{c c c c c c c } \hline \begin{timessample}{c c c c c c c c c c c c c c } \hline \begin{timessample}{c c c c c c c c c c c c c c c c c c c $							
Age Dateobject objectpatient age test datechild - adultDateobject objecttest dateChInt64Cholesterol, serum, mg/dLMale 60 -160Fernale 40 - 140HDLInt64Triglyceride, serum, mg/dLMale (60 - 160)Fernale 35 - 70LDLfloat64low-density lipoprotein $-65 - 178$ mg/dLBu/UrInt64Blood urea, plasma or serum $20 - 45 \text{ mg/dL}$ Bu/UrInt64Blood urea, plasma or serum, mg/dL $0.7 - 1.2$ Crfloat64Creatinine, serum, mg/dL $0.7 - 1.2$ Uafloat64Uric acid, serum $0.7 - 1.2$ Uafloat64Arminotransferase, serum alarine $-5 - 65$ U/LALT, SGOTInt64Aminotransferase, serum alarine $-5 - 65$ U/LALPInt64alkaline phosphatase, serum, 20 area108 - 317Int64Aminotransferase, serum alarine $-5 - 05$ U/LALPInt64Bloaton $-3 - 37 mg/dL$ Int64Jaber $-5 - 5 U/L$ years $-5 - 5 - 5 - 65$ U/LALPInt64Alarine serumInt64Alarine serum $-5 - 150 mg/dL$ years $-5 - 15 mg/dL$ $-5 - 150 mg/dL$ yearsInt64Fernale					M - F		
$ \begin{array}{ c c c c } \hline Date & object & iest date \\ \hline Ch & Int64 & Cholesterol, serum, mg/dL & Male & Female \\ \hline Ch & Int64 & Triglyceride, serum, mg/dL & Male & Female \\ \hline 60 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 40 - 160 & 40 - 140 \\ \hline 35 - 65 & 35 - 70 \\ \hline 1DL & float64 & Iow-density lipoprotein & 5 - 178 mg/dL \\ \hline Bu/Ur & Int64 & Blood urea, plasma or serum & 20 - 45 mg/dL \\ \hline Bu/Ur & Int64 & Oreatinne, serum, mg/dL & Male & Female \\ \hline 10 - 10 & 1064 & Creatinne, serum, mg/dL & Male & Female \\ \hline 10 - 10 & 1064 & Aminotransferase, serum alanine & 5 - 65 U/L \\ ALT, SGPT & Int64 & Aminotransferase, serum aspartate & 5 - 05 U/L \\ \hline ALT, SGOT & Int64 & Aminotransferase, serum aspartate & 5 - 05 U/L \\ \hline 11 - 30 days & 48 - 406 & 75 - 31 \\ \hline 1 - 30 days & 48 - 406 & 75 - 31 \\ \hline 1 - 30 days & 48 - 406 & 75 - 31 \\ \hline 1 - 30 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 40 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 3 0 days & 48 - 406 & 75 - 31 \\ \hline 1 - 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 20 mg/dL \\ \hline 1 0 at64 & morealized ratio \\ 0 - 1 - 1 20 mg/dL \\ \hline 1 - 1 20 mg/dL \\ \hline 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 - 1 - 1 1 - 1 - 1 20 mg/dL \\ \hline 1 - 1 - 1 - 1 - 1 - 1 - 1 1 \\ \hline 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 \\ \hline$							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						Guit	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		-			<	200  mg/dL	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$						-	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		into i	mgrycenae, seram, mg/an				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	HDL	Int64	high-density lipoprotein, mg/dL				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	LDL	float64	low-density lipoprotein				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						U	
Uafoat64Uric acid, serum $0.7 - 1.2$ $0.5 - 1$ Uafloat64Uric acid, serum $3 - 7 mg/dL$ ALT, SGPTInt64Aminotransferase, serum alanine $5 - 65$ U/LALPInt64alkaline phosphatase, serum, u/LAgeFemaleMale $1 - 30$ days48 - 40675 - 31104 - 3452383 $1 - 3 y cars108 - 317104 - 34523 - 3831 - 3 y cars108 - 317104 - 34523 - 33831 - 3 y cars96 - 29793 - 30993 - 3097 - 9 y cars69 - 32586 - 3151 - 12 y cars51 - 33242 - 362y cars16 - 18 y cars47 - 11952 - 171y cars20 - 5042 - 9853 - 128y cars20 - 5042 - 9853 - 128y cars10 - 12 y cars10 - 0.30.2 - 0.7IronInt64Iron, serumfoatalDirect0.3 - 1.00.2 - 0.7IronInt64Fast Blood Sugar70 - 120 mg/dL0.2 - 0.7IronInt64Random Blood Sugar70 - 120 mg/dL0.8 - 1.1FBSInt64Random Blood Sugar0.8 - 1.10.8 - 1.1IrotalInternational normalized ratio0.8 - 1.10.8 - 1.1IrotalInternational normalized ratio0.8 - 1.10.8 - 5.5INRfloat64Patrial thromboplastin time30 - 40 secondsINRInt64Random Blood Sugar0.4 - 9.5 - 5.2<$			*				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	CI	110at04	creatinine, seruni, ing/uL				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		float64	Uric acid, serum			3-7 mg/dL	
$\begin{tabular}{ c c c c c c c } ALP & Int64 & alkaline phosphatase, serum, U/L & Age & Female & Male \\ \hline $1-30 \ days & 48-406 & 75-31 \\ \hline $1-30 \ days & 48-406 & 75-31 \\ \hline $1-30 \ days & 108-307 & 104-345 \\ \hline $2-383 & 1-3 \ years & 108-317 & 104-345 \\ \hline $4-6 \ years & 96-297 & 93-309 \\ \hline $7-9 \ years & 69-325 & 86-315 \\ \hline $10-12 \ years & 51-332 & 42-362 \\ \hline $10-12 \ years & 51-332 & 42-362 \\ \hline $10-12 \ years & 51-332 & 42-362 \\ \hline $years & 16-18 \ years & 47-119 & 52-171 \\ \hline $20 & -50 & 42-98 & 53-128 \\ \hline $years & 16-18 \ years & 47-119 & 52-171 \\ \hline $20 & -50 & 42-98 & 53-128 \\ \hline $years & 16-18 \ years & 70-120 \ mg/dL & 0.1-0.3 & 0.2-0.7 \\ \hline $Iron & Int64 & Iron, serum & 65-180 \ mg/dL \\ FBS & Int64 & Fast Blood Sugar & 70-120 \ mg/dL \\ ALB & Iloat64 & Albumin, serum & 65-180 \ mg/dL \\ RBS & Int64 & Fast Blood Sugar & 70-120 \ mg/dL \\ ALB & Iloat64 & neron serum & 65-2 \ g/dL \\ PT & Iloat64 & international normalized ratio & 0.8-1.1 \\ RBS & Int64 & Random Blood Sugar & 80-130 \ mg/dL \\ PTT & Iloat64 & international normalized ratio & 0.8-1.1 \\ RBS & Int64 & Random Blood Sugar & 80-30 \ mg/dL \\ PTT & Iloat64 & International normalized ratio & 0.8-1.1 \\ RBS & Int64 & Random Blood Sugar & 80-30 \ mg/dL \\ PTT & Iloat64 & Hemoglobin A1C & 4.2\% - 6.2\% \\ \hline \hline & Electrolytes, serum, mm/L \\ Na & Int64 & Patrial thromboplastin time & 30-40 \ seconds \\ HBA1C & float64 & Hemoglobin A1C & 4.2\% - 6.2\% \\ \hline \hline & Electrolytes, serum, mm/L \\ \hline Na & Int64 & Potassium & 3.6-5.5 \\ Cl & Int64 & Chloride & 98-111 \\ \hline \hline $66PD & object & Glucose-6-phosphate dehydrogenase & normal - deficient \\ \hline & Store \ analysis \\ \hline \hline & Scolor & Object & color \\ \hline & Scize & Iloat64 & size, cm \\ \hline \hline \hline \end{tabular}$	ALT, SGPT	Int64	Aminotransferase, serum alanine			5-65  U/L	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	AST, SGOT	Int64	Aminotransferase, serum aspartate	•		<50 U/L	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	ALP	Int64	alkaline phosphatase, serum, U/L	Age	Female	Male	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$				1 - 30 days	48 - 406	75 - 31	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$				1mon - 1year	124 - 341	82 - 383	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$				1-3 years		104 - 345	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$				4-6 years			
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$							
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$							
$\begin{tabular}{ c c c c c c c } \hline $$ years$ & $47-119$ & $52-171$ \\ \hline $$ 16-18$ years$ & $47-119$ & $52-171$ \\ \hline $$ 20$ - 50$ & $42-98$ & $53-128$ \\ \hline $$ years$ & $$ 10at64$ & $$ Bilirubin, serum, mg/dL$ & $$ Total$ & $$ Direct$ & $$ InDirect$ \\ \hline $$ 10at64$ & $$ Bilirubin, serum, mg/dL$ & $$ 10at64$ & $$ 11at64$ & $$ 11at64$$				•			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							
years-AniiTSBfloat64Bilirubin, serum, mg/dLTotal 0.3 - 1.0Direct 0.1 - 0.3InDirect 0.2 - 0.7IronInt64Iron, serum $65 - 180 \text{ mg/dL}$ FBSInt64Fast Blood Sugar $70 - 120 \text{ mg/dL}$ ALBfloat64Albumin, serum $3.6 - 5.2 \text{ g/dL}$ PTfloat64prothrombin time $11 - 13.5 \text{ seconds}$ INRfloat64international normalized ratio $0.8 - 1.1$ RBSInt64Random Blood Sugar $80 - 130 \text{ mg/dL}$ PTTInt64Partial thromboplastin time $30 - 40 \text{ seconds}$ HBA1Cfloat64Hemoglobin A1C $4.2\% - 6.2\%$ NaInt64Sodium, Natrium $136 - 155$ Kfloat64Potassium $3.6 - 5.5 \text{ cl}$ ClInt64Sodium, Natrium $3.6 - 5.5 \text{ cl}$ G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorsize, cm				47 - 119	52 - 171		
Image: Constraint of the second se				20 – 50	42-98	53-128	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		years					
IronInt64Iron, serum $0.3 - 1.0$ $0.1 - 0.3$ $0.2 - 0.7$ IronInt64Iron, serum $65 - 180$ mg/dLFBSInt64Fast Blood Sugar $70 - 120$ mg/dLALBfloat64Albumin, serum $3.6 - 5.2$ g/dLPTfloat64prothrombin time $11 - 13.5$ secondsINRfloat64international normalized ratio $0.8 - 1.1$ RBSInt64Random Blood Sugar $80 - 130$ mg/dLPTTInt64Partial thromboplastin time $30 - 40$ secondsHBA1Cfloat64Hemoglobin A1C $4.2\% - 6.2\%$ Electrolytes, serum, mmol/LNaInt64Sodium, NatriumNaInt64Potassium $3.6 - 5.5$ ClInt64Potassium $3.6 - 5.5$ ClInt64Sodium, Natrium $136 - 155$ Kfloat64Potassium $3.6 - 5.5$ ClInt64Sodium, Natrium $136 - 155$ Kfloat64Potassium $3.6 - 5.5$ ClInt64Chloride $98 - 111$ G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorsize, cm							
IronInt64Iron, serum65 – 180 mg/dLFBSInt64Fast Blood Sugar70 – 120 mg/dLALBfloat64Albumin, serum3.6 – 5.2 g/dLPTfloat64prothrombin time11 - 13.5 secondsINRfloat64international normalized ratio0.8 – 1.1RBSInt64Random Blood Sugar80 – 130 mg/dLPTTInt64Partial thromboplastin time30 – 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% – 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, NatriumNaInt64PotassiumG6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorS-sizefloat64size, cm	TSB	float64	Bilirubin, serum, mg/dL				
FBSInt64Fast Blood Sugar70 – 120 mg/dLALBfloat64Albumin, serum3.6 – 5.2 g/dLPTfloat64prothrombin time11 - 13.5 secondsINRfloat64international normalized ratio0.8 – 1.1RBSInt64Random Blood Sugar80 – 130 mg/dLPTTInt64Partial thromboplastin time30 – 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% – 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, NatriumNaInt64PotassiumG6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorS-sizefloat64size, cm				0.3 - 1.0			
ALBfloat64Albumin, serum $3.6-5.2$ g/dLPTfloat64prothrombin time $11 - 13.5$ secondsINRfloat64international normalized ratio $0.8 - 1.1$ RBSInt64Random Blood Sugar $80 - 130$ mg/dLPTTInt64Partial thromboplastin time $30 - 40$ secondsHBA1Cfloat64Hemoglobin A1C $4.2\% - 6.2\%$ Electrolytes, serum, mmol/LNaInt64Sodium, NatriumNaInt64PotassiumG6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorS-sizefloat64size, cm							
PTfloat64prothrombin time11 - 13.5 secondsINRfloat64international normalized ratio0.8 - 1.1RBSInt64Random Blood Sugar80 - 130 mg/dLPTTInt64Partial thromboplastin time30 - 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% - 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, Natrium136-155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorSize, cm							
INRfloat64international normalized ratio0.8 – 1.1RBSInt64Random Blood Sugar80 – 130 mg/dLPTTInt64Partial thromboplastin time30 – 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% – 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, NatriumNaInt64PotassiumG6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorS-sizefloat64size, cm							
RBSInt64Random Blood Sugar80 – 130 mg/dLPTTInt64Partial thromboplastin time30 – 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% – 6.2%Int64Bectrolytes, serum, mmol/LInt64Sodium, NatriumNaInt64Sodium, Natrium136–155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorsize, cm							
PTTInt64Partial thromboplastin time30 – 40 secondsHBA1Cfloat64Hemoglobin A1C4.2% – 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, Natrium136–155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorsize, cm							
HBA1Cfloat64Hemoglobin A1C4.2% - 6.2%Electrolytes, serum, mmol/LNaInt64Sodium, Natrium136-155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientS-colorobjectcolorsize, cm						U	
Electrolytes, serum, mmol/LNaInt64Sodium, Natrium136–155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientStone analysisS-colorobjectcolorS-sizefloat64size, cm							
NaInt64Sodium, Natrium136–155Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientStone analysisS-colorobjectcolorS-sizefloat64size, cm	HBA1C	float64	Hemoglobin A1C			6 - 6.2%	
Kfloat64Potassium3.6-5.5ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientStone analysisS-colorobjectcolorS-sizefloat64size, cm							
ClInt64Chloride98-111G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientStone analysisS-colorobjectcolorS-sizefloat64size, cm							
G6PDobjectGlucose-6-phosphate dehydrogenasenormal - deficientStone analysisS-colorS-sizefloat64size, cm							
Stone analysis   S-color object   S-size float64		Int64					
S-colorobjectcolorS-sizefloat64size, cm	G6PD	object				- deficient	
S-size float64 size, cm			Stone analysis				
S-consistency object consistency							
	S-consistency	object	consistency				

S-ca	Int64	64 Calcium			found=1, not-found=0		
S-ox	Int64	54 Oxalate			found=1, not-found=0		
S-po4				found=1, not-found=0			
S-ua	ua Int64 Uric Acid			found=1, not-found=0			
S-carbonate	Int64	carbonate		found=1, not-found=0			
S.Amylase	Int64	Amylase, serum		<86 U/L			
S.Lipase	Int64	Lipase, serum	< 38 U/L				
Zinc	float64	Zinc, serum		72.6 – 127 mg/dL			
Ca	float64	Calcium, serum		8.5-10.5 mg/dL			
CRP	float64	C-reactive protein, serum		<5 mg/L			
Po4	float64	Phosphorous, serum, mg/dl	L Childı	en Male	Female		
		1 / / 2	4–7	2.5-4.			
	24-hour urine test		I				
ur 24-cr	float64	Creatinine		1 - 2 g/24	4hr		
ur 24-ua	Int64	Uric acid	25	0 - 750  mg/			
ur 24-ca	Int64	Calcium		00 - 350  mg			
ur 24-po4	float64	Phosphate		0.4 – 1.3 g			
ur 24-protein	float64	Protein	1		5 - 4.5  g/24hr		
ur 24-alb	float64	Albumin			<2.3 mmol/L		
ur 24-ox	float64	Oxalate	<0.50 mmol/L				
ur 24-citrate	object			ositive - neg	itive - negative		
ur 24-cu	float64	Copper			20 - 50  mg/24 hr		
ur 24 amylase	Int64	Amylase		1 - 17 U/24hr			
CK, CPK	Int64	Creatine kinase, serum, Child		Male	Female		
,	U/L	<225		<174	<140		
TIBC	Int64	total iron-binding capacity, serum		250 -	- 400 mg/dL		
BJP	object	Bence-Jons			e - negative		
LDH	Int64	lactate dehydroge	-		– 414 U/L		
Mg	float64	Magnesium, serum, mmol/L	Childr	lren Adult			
C			1.7 - 2.5	1.7 – 2.3 1.6 – 3			
GTT (1, 2, 3, 4, 5)	Int64	Glucose Tolerance Test	(75gms)	70 – 120 mg/dL			
,	Complement compo	nents, serum, mg/dL					
C3	Int64	×		91 -	- 156		
C4	float64			20 -	- 50		
Cu	float64	Copper, serum, mg/dl	L Man (70-	14)			
			Women (	80 - 155)			
			Women H	Women Pregnancy (120 – 300)			
				Children up to 1-year $(80 - 190)$			
				Newborns $(20-70)$			
ACP	float64				0.5–2.0 U/mL		
GGT, g-GT	Int64	Gamma-glutamyl transpeptidase, serum, U/L Male Fe		Female			
				<49	<32		
TSP	float64	Total serum protein		1	- 8 g/dL		
Fe	Int64 Ferritin, serum, ng/mL M		Male	Female			
				30-400	13-150		
Lupus	object	Lupus, Anti-lupus		positive –	- negative		

Often, there are no specific symptoms of high cholesterol. The extra cholesterol may be stored in the arteries as plaques, which leads to narrow arteries. Therefore, patients have to check the other cholesterol tests that include Tri, HDL, and LDL. Where, Tri is another type of cholesterol, which its level increasing leads to arteries hardening. As well as, LDL is called "bad" cholesterol, since its excessed amount in the blood leads to heart attack or stroke. Thus, LDL value could be calculated using equation 1.

Meanwhile, the Bu/Ur test is used to diagnose kidney diseases. In the case of kidney disease, the Bu/Ur level will be high in the blood. In contrast, the Bu/Ur decreases in liver disease cases due to its inability to form it. Whereas, any disease that causes kidney weakness could lead to high Cr test, such as diabetes, high blood pressure. Likewise, the TSB test as a total is for children to measure the percentage of bilirubin. When TSB increasing, mean there is jaundice. Despite the fact that TSB test is calculated to direct/indirect for an adult to measure the liver enzymes, and for supporting the doctors in determining the liver disease treatment. Meanwhile, the prothrombin protein produced by the liver, is one of many blood factors that helps to clot appropriately. Where, the PT test determines how quickly blood clots. It's often performed along with PTT test, which looks at another set of factors. When patients take blood thinners such as heparin, warfarin, and aspirin, then the prothrombin time test results will be expressed as INR test <sup>10</sup>.

#### **Methods of Work:**

There are several DM techniques implemented, the unsupervised techniques were used firstly because the investigated laboratory dataset has no specific class. However, the applied experiments on this dataset are discussed in the below subsections.

#### **Experiment 1**

In Experiment 1 the clustering through hierarchical technique was applied by orange platform V3.22.0. Thereafter, the hierarchical technique clustered patients into subgroups, these subgroups are then merged into larger groups, then formatting the hierarchical tree. The distance computation have default imputation for null values, either by the average of row or of column. Hence, agglomerative strategies had been used with parameters, Euclidian distance metric, normalization, no pruning, whereas the selection was manual, and the linkage was average based as formulated in equation 2<sup>11</sup>:

 $mean_i ||a_i - b_i|| \dots \dots \dots \dots \dots \dots (2)$ 

Where,  $a_i$  and  $b_i$  are all objects in clusters a and b. Anyway, this technique offers a dendrogram that is a tree like-diagram, which records the sequences of merges. The drawback is the determination of the clusters number should be manually, here k has been set as 3. Therefore the silhouette algorithm for detection the cluster number were used. The produced result as represented in Fig. 1.




Figure 1. Hierarchical clustering algorithm using Orange platform.

### **Experiment 2**

In experiment 2 a Silhouette algorithm was applied to determine clusters number for *k*-means approach. The used platform was orange too. Thus, Silhouette has a drawback because it cannot be applied to null values. As a consequence, filling was based on the average of each feature. Also, this algorithm doesn't work with more than 5000 instances. Hence, the result explored two clusters with a high score. Then, the *k*-means algorithm was applied with k=2. The first produced cluster contained 2873 patients, while the second cluster contained 2127 patients. Accordingly, the silhouette algorithm scores are shown in Fig. 2.

Silhouette scores for different numbers of clusters					
0.256					
0.226					
0.217					
-0.054					
-0.042					
-0.152					
-0.151					

Figure 2. The Silhouette algorithm produced two clusters of the highest score.

However, for a dataset *D* of *n* objects, if *D* is split to *k* clusters  $C_1, ..., C_K$ . Then, for each object  $o \in D$ , a(o) is calculated as the average distance between

*o* and all other objects in the cluster that *o* belongs to. On the other hand, b(o) is the minimum average distance from *o* to all clusters that *o* do not belong to. Then, for  $o \in C_i$   $(1 \le i \le k)$ . In this manner, the distances are determined as shown in equations 3 and 4 respectively <sup>12</sup>.

$$a(o) = \frac{\sum_{o' \in C_{i,o \neq o'}} dist(o,o')}{|C_i| - 1} \dots \dots \dots \dots (3)$$
$$b(o) = \left\{ \frac{\sum_{o' \in C_j} dist(o,o')}{|C_j|} \right\} \dots \dots \dots (4)$$

Then, the Silhouette coefficient of o is determined as in equation 5<sup>12</sup>.

$$s(o) = \frac{b(o) - a(o)}{\{a(o), b(o)\}} \dots \dots \dots \dots \dots \dots (5)$$

Where, the result of equation 5 is ranging between - 1 and 1. While, the value of a(o) indicates the cluster agglomerating to which object belongs. Whenever this value becomes smaller, hence the cluster is more agglomerated. Meanwhile, the value of b(o) indicates the object far away degree from other clusters. Whenever the value becomes larger, then the object will be more separated from other clusters <sup>12</sup>.

# **Experiment 3**

The dataset had many null values, which cannot be filled by approximate values, because this will lead to loss information and give wrong result. Also, the dataset features cannot be reduced by any dimensional reduction technique, because it may lead to probable loss important features. Since, CART will be used, the dataset did not need normalization process. Thus, a supervised principle has been used by applying multi-steps beginning with preprocessing which is the most important step, and then several DM algorithms have been examined on the dataset in order to select the highest accuracy one. In this way, these steps are described in the following sections:

# **Preprocessing Step**

In order to perform the preprocessing phase, python v. 3.7.0. have been used. Thus, adding the index feature was the first step, where a unique number was added for dataset indexing. So, an index object has been used, where pandas library v. 0.25.1 provides it. Moreover, the age feature has been added to the dataset based on some tests by clinical laboratory physician support, as it has been assumed that the tests of children were (TSB, Ca, ALB, Bu,

G6PD, RBS), while the remaining tests for adults. However, Adding Age Feature has been determined as in algorithm 1.

**Algorithm 1: Adding Age Feature** Input: X Output: X with age feature Function CreTestLst(X):  $L1 \leftarrow X[TSB].notna(),$ X[Ca].notna(), Set X[ALB].notna(), X[Bu].notna(),X[G6PD].notna(), X[RBS].notna() Set  $L2 \leftarrow X$  not in L1Set  $N \leftarrow \text{len}(X)$ ComTestAdd(X, L1, L2, N)return X **End Function** Function ComAgeAdd(*X*,*L1*,*L2*,*N*): Set *X*[age]←nan for  $i \leftarrow 0$  to N do if X in L1 then Set *X*[age]←*child* end if X in L2 and not in L1 then Set  $X[age] \leftarrow adult$ end end **End Function** 

Whereas X is the indexed dataset, N is the length of X, L1 is the list for children tests names, L2 is the list for adult tests names, and *i* is a temporary variable. Also, the gender feature that was added depending on standard names in Iraq, assuming that common names are for females, because of their majority in Iraq, as determined in algorithm 2.

**Algorithm 2: Adding Gender Feature** Input: X Output: *X* with gender feature Function CreNamesLst(X): Set *L1*←[*standard names for male*] Set  $N \leftarrow \text{len}(X)$ ComGenAdd(X, L1, N)return X **End Function** Function ComGenAdd(X, L1,N): Set *X*[gender]←nan for  $i \leftarrow 0$  to N do if X in L1 then Set X[gender] $\leftarrow$ 'M' else Set X[gender]  $\leftarrow$  'F' end end **End Function** 

Whereas, X is the indexed dataset with age feature, N is the length of X, L1 is the list of standard male names, and i is a temporary variable. While, the date feature was added depending on the recorded date in the registry hard copy. This feature was added as in algorithm 3.

### **Algorithm 3: Adding Date Feature**

Input: *X*,*FDate* Output: X with date feature Function ComDateAdd(*X*,*FDate*,*N*,*j*,*k*): Set *X*[date]←nan Set  $N \leftarrow \text{len}(X)$ for  $i \leftarrow 0$  to N do if i > = i and i < = k then Set *X*[date]←*FDate* else Set  $j \leftarrow k+1$ Set *k*←*k*+100 Set  $FDate \leftarrow New Date$ end end return X **End Function** 

Where, X is the indexed dataset with age and gender features, FDate is the first date in the registry hard copy, New Date is the next date, N is the length of X, and i,j,k are temporary variables. Hence, data cleaning is necessary because null values make a big problem in the data analysis field. Therefore, they should be removed. Regarding the clinical laboratory dataset, the splitting has been performed depending on similarities with features names, where a number of smaller separated datasets files has been created without null values. The number of resulting datasets is 609, which consist of many outliers datasets that have been removed by putting a thresholds, which is equal to 50 for sample size and 3 for number of tests features at least. This procedure has been performed via algorithm 4.

# Algorithm 4: Splitting Dataset

Input: *X* Output: Split datasets as excel files Function CreColLst(*X*): Set  $N \leftarrow \text{len}(X)$ Set  $j \leftarrow 0$ Set  $m \leftarrow 0$ for  $i \leftarrow 0$  to *N* do Set  $k[j] \leftarrow X[i]$ .columns names Set  $j \leftarrow j+1$ if k[j] not in *x* and len(*k*) > 2 then Set  $x[m] \leftarrow k[j]$ Set  $m \leftarrow m+1$ 

end end return x End Function Function CreSplit(*X*): Set m←0 for  $i \leftarrow 0$  to 608 for  $i \leftarrow x[0]$  to x[608] do X[i].drop row that contains a null value at column names Set  $K[m] \leftarrow X[i]$ .index values Set  $m \leftarrow m+1$ X[i].write to excelfiles (j) X.drop(K)end end return *excelfiles* End Function Function DelFiles(*excelfiles*): for  $i \leftarrow 0$  to 608 do Set  $a \leftarrow \text{len}(excelfiles(i))$ if a < 50 then Delete(excelfiles(i)) end end End Function

Whereas X is the indexed dataset with age, gender, and date features, N is the X length, k is the columns names list, x is the list of column names list without repeating, and *K* is the index list, which is same column names list in X, and i, j, m, a are temporary variables. As well as, data visualization step was needed because the human grasp a lot of information from diagrammatic representation. Thus, it is better to visualize dataset splitting through visualization techniques. So, a scatter plot function in the Seaborn library v. 0.10.1 has been used for plotting splitted datasets. Thereby, it assists in clarifying the relation between features, such as represented in Fig. 3. Thereafter, the splitted datasets have been grouped depending on several common features between them. Where the chemical tests should be splitted from personal information. The result was six groups of splitted datasets, the first group has four common features (Ch, Tri, HDL, LDL). Then, the second group has three common features (FBS, RBS, HBA1C). And, the third group has two common features (Iron, TIBC). While the fourth group has three common features (PT, INR, PTT). And, the fifth group has two common features (TSB, Direct). As well as, the sixth group has two common features (Bu, Cr). Accordingly, the grouping process was designed as algorithm in 5.




Figure 3. Plot of one splitted data sets with four common features (Ch, Tri, HDL, LDL, FBS)

**Algorithm 5: Grouping Dataset** 

Input: F Output: list of common features Function CalCF(*F*): for  $k \leftarrow 1$  to len(*F*) do  $\operatorname{Set} f \leftarrow F[k]$ ComFea(f) end **End Function** Function ComFea(*f*): Set *X*  $\leftarrow$  read max length dataset from *f* Set  $L \leftarrow X$ .column names L.delete elements from 0 to 5 For  $i \leftarrow 0$  to len(f) Set *X*1 $\leftarrow$ read dataset from *f* Set  $L1 \leftarrow X1$ .columns names L1.delete elements from 0 to 5 for  $i \leftarrow 0$  to len(L) If L[j] not in L1 then

L.remove(j) end end end return L End Function

Whereas, F is the groups file, f is one of the group elements, X is the longest excel file in f. While X1 is a temporary variable for the rest excel files, L and L1 are the lists of columns names, and k,i,j are temporary variables. And then, data discretization process has been applied for each common feature to convert data type from numeric to nominal values relying on the normal reference of tests as explored in Table 2, then to be assumed as classes. The discretization technique provided by python was unhelpful, thus algorithm 6 has been developed for this process using Table 2.

Table 2. nominal	values for	assumed classes
------------------	------------	-----------------

TESTS	NOMINAL VALUES		
Ch	C1: if Ch < = 200 (Normal)	C2: if Ch > 200 (High)	
Cr	Cr1: if Cr < 0.7 (Low)	Cr2: if Cr $\ge$ 0.7 and Cr $\le$ 1.2 (Normal)	Cr3: if Cr >1.2 (High)
Direct	D1: if Direct < 0.1 (Low)	D2: if Direct $\ge 0.1$ and Direct $\le 0.3$ (Normal)	D3: if Direct > 0.3 (High)
INR	IN1: if INR < 0.8 (Low)	IN2: if INR $\geq$ 0.8 and INR $\leq$ 1.1 (Normal)	IN3: if INR > 1.1 (High)
PT	P1: if PT < 11 (Low)	P2: if $PT \ge 11$ and $PT \le 13.5$ (Normal)	P3: if PT > 13.5 (High)
TSB	T1: if TSB < 0.2 (Low)	T2: if TSB $\ge 0.2$ and TSB $\le 0.7$ (Normal)	T3: if TSB > 0.7 (High)

Algorithm Features	6: Discr	etization	Common
2 00002 05			
Input:	• 11	· 10	• 10
<i>F,L,NR</i> 1, <i>NR</i> 2,			
Output: X w	ith nomina	l values	at common
features			
Function		10	CalDisc( $F,L$ ,
NR1,NR2,nom		al2,nomi	nal3):
for $k \leftarrow 1$ to let	n(F) do		
$\operatorname{Set} f \leftarrow F[k]$			
Disc(f,L NR1,I	VR2,nomina	l1,nomin	al2,nominal3)
end			
End Function			
Function			Disc(f,L
NR1,NR2,nom	inal1,nomin	al2,nomi	nal3):
Set $X \leftarrow$ read da	ataset from	f	
Set $L1 \leftarrow X.cold$			
if $L1 == L$ then	1		
For $i \leftarrow 0$ to len	$\mathbf{I}(X)$		
if $X[L1,i] < NR$	( )		
X[L1,i].replace		)	
else if <i>X</i> [ <i>L1</i> , <i>i</i> ]	≥ <i>NR</i> 1 and	$\leq NR2$ th	ien
X[L1,i].replace	e('nominal2	')	
else $X[L1,i]$ . re	place('nomi	nal3')	
end	· ·	,	
end			
end			
End Function			
$\frac{1}{1}$ where $F$ is the	groups file	e Lis	the common

Where, F is the groups file , L is the common features list , NR1 and NR2 are normal range values for common features (tests), *nominal1,nominal2*, and *nominal3* represent nominal values for assumed classes (features), f is one of the group elements, X is *excel file* in f, L1 is the list of features names, and k,i are temporary variables.

#### **Feature Selection**

The feature selection technique is very useful in improving the accuracy by finding the

dtype='object')

highest impact features on the class value with less training time, and memory efficiency. However, feature selection algorithms are subdivided into supervised, and unsupervised. Hence, the two feature selection techniques which provided by sklearn library v. 0.22.1 have been used on a splitted dataset sample. Firstly variance-threshold technique has been used, which is unsupervised that employs the reducing feature principle, where predetermined probability is used in calculating threshold according to equation 6<sup>13</sup>, which is used at the same time in calculating feature variance when using feature probability:

 $Var[X] = p(1-p) \dots \dots \dots \dots \dots \dots (6)$ 

Where, p reflects predetermined probability, and feature values probability. If feature variance values less than a threshold, then it should be ignored. It was unhelpful in the clinical laboratory dataset, because the features have high variance, they are numeric with different values. Eventually. Recursive Feature Elimination (RFE) which is a supervised technique that starts with all dataset features, builds a model, and ignores the irrelevant features according to the model. Then, a new model has been built using the rest features, and so on until a predetermined number of features are left <sup>14</sup>. Thus, it needs to determine the features number and the model. Then, three used for features number, and the decision tree classifier with a criterion of 'gini' as a model. It was applied to one of the split datasets that assumed (Ch) feature as a class. So, the result supports the selected features list, features ranking list. Whereas, the chosen features have rank=1, and best features list, such as represented in Fig. 4.

### Figure 4. The RFE results for one of the splitted datasets.

In RFE with cross - validation (RFECV) of 10fold , tuning the predetermined number of features such as in Fig. 5. Optimal number of features : 2 Selected Features: [False False True False True] Feature Ranking: [11 10 1 9 8 7 6 5 4 3 2 1] accuracy: 0.94166666666668 Best features : Index(['LDL', 'Direct'], dtype='object') Original features : Index(['idx', 'names', 'Age', 'Gender', 'Date', 'Ch', 'Tri', 'HDL', 'LDL', 'Ur', 'Cr', 'Ua', 'Gpt', 'Got', 'Alp', 'TSB', 'FBS', 'Direct'],

Figure 5. RFECV technique results for one of the splitted datasets.

### **Data Mining Algorithms**

Several DM algorithms that Sklearn library provided have been used firstly. The 10 fold cross – validation has been used as a performance metric to evaluate each algorithm. Also the dataset has been splitted to 80% for training and 20% for testing evaluation. Actually, LR, LDA, CART, K-NN, NB, and SVM have been applied on the splitted dataset, where (Ch) feature as the assumed class with 61 sample. Hence, the results were the accuracy mean of 10-fold, and the testing accuracy as shown below in Table 3. Indeed it's obvious that CART algorithm has the highest accuracy of 0.93, and 0.92 respectively. Thus it has been used as an analysis model.

Table 3. Accuracy results for DM algorithm.

			/		0	
DM	LR	CA	NB	LD	SVM	KN
algorithms		RT		А		Ν
10-fold	0.91	0.93	0.85	0.90	0.59	0.89
accuracy						
Testing	0.77	0.9	0.6	0.8	0.6	0.7
accuracy		2	9	5	9	7

The concept of cross-validation mean split the dataset into k parts of equal size then, k-1 using for training, and the rest 1 for testing. The process of cross-validation repeat k times in order to avoid bias in result. Commonly in evaluation of algorithms, researchers either use the k-fold or training-testing accuracy, which mean split the dataset for two parts, training and testing. Generally, the size of training be 75% or 80%, so for testing using 25% or 20% of the dataset. This process run only one time.

### Classification and Regression Trees (CART) Algorithm

The Classification and Regression Trees (CART) approach constructs a binary tree, where each internal node denotes a condition on a feature, each of the two branches corresponds to a conditional outcome (true and false), and each leaf node denotes a class label. This algorithm chooses the "best" feature at each node to separate the data into individual classes. The tree becomes binary depending on the feature selection measure. Some feature selection measures, such as the 'gini' index, enforce the resulting tree to be binary. Others, like information gain, which allow multiway splits <sup>12,14</sup>. Also, the 'gini' feature gain can be obtained by measuring the 'gini' index for all feature values of which belongs to the dataset. As well as, when the pruning is not used, then the building process of decision tree will select the gini-gain of the smallest node, which is the branching point until the subdatasets belong to the same class or all the features

are used in building the tree. So, for dataset T, the 'gini' is determined as in equation 7<sup>14</sup>:

Where *n* is the number of classes and  $p_j$  is the probability of different classes for the dataset samples. Gini split info, which measures the gini index for all feature values, which is determined according to equation 8<sup>14</sup>:

$$gini_{split}(T) = \sum \frac{N_i}{N}gini(T_i)\dots\dots\dots(8)$$


Where *i* represents the i - th feature value. And, the gain is the same, which is also called gini information gain (gini-gain). Likewise, for CART, i = (1,2), get gini gain in binary split according to equation 9<sup>14</sup>:

$$gini_{split} (T) = \frac{N1}{N}gini(T1) + \frac{N2}{N}gini(T2) \dots \dots (9)$$


because the algorithm relies on the principle of the binary tree, so concerning continuous data, a discretization process used on the data by considering it not continuous for one sample, such that if there are N samples, this means that there is N-1 of the split results, the right sub-tree represents values bigger than, while the left sub-tree represents values less and equal to the parent node. In order to reduce the computations for the discretization process, the feature have been arranged in ascending order and select midpoint as a division point which divides the data into two parts, likewise calculate the gini-gain for each possible division point. But here the improvement with this algorithm is to calculate gini-gain for only the distinct values of the classification attribute change. Then choose the value with the lowest gini-gain as the best separation point.

# **Model Implementation**

In this paper, the model has been built using the CART algorithm with k - fold cross - validation performance metric. The parameters for CART were 'gini' for criterion, 7 for random\_state value, and 3 for max\_depth value. *K-fold* algorithm parameters were 10 for *K* and 7 for random\_state. Hence, Fig. 6 below shows the model design.



However, each group of common features has been expanded to a number of groups equal to a number of common features. Then each common feature in the group has been assumed as a class. After applying the CART algorithm in the orange platform and python language, the same result has been obtained. But, the accuracy of some assumed classes was low, therefore they have been ignored. Then, high accuracy assumed classes were, Ch, Cr, TSB, PT, INR, and Direct. The tree has been visualized by using the matplotlib v 3.1.1 library as shown in the following Fig. 7-13.






Figure 9: Pattern of PT feature with INR class.




Figure 12. Pattern of Ur feature with Cr class.




Figure 13. Pattern of TSB feature with Direct class.

### **Results and Discussion:**

The resulting accuracy of patterns was determined as 10 - fold cross - validation. The resulting patterns were LDL value decreasing does not affect Ch value, it stavs normal, while LDL increasing leads to Ch increasing with an accuracy of 0.97 and 0.96. Also, Tri decreasing does not affect the value of the Ch with an accuracy of 0.97. While, the decrease of Cr value affects by increasing the Ch value with an accuracy of 0.96. Although, the Bu/Ur value does not affect the Cr value (there is no relation between them) with an accuracy of 0.93. Furthermore, the increasing of Direct does not affect the TSB value with an accuracy of 0.95. On the other hand, the decrease in TSB value affects Direct by decreasing it, while the increase in TSB does not affect direct value with an accuracy of 0.97. The INR value increasing does not affect the PT value, while when decreasing leads to low PT with an accuracy of 1.0. Also, when PT value decreasing leads to low INR, and when increasing, the value of the INR stays normal with an accuracy of 1.0<sup>10</sup>.

# **Conclusions:**

This paper presented the experiments which could be applied to this type of dataset for discovering the patterns of relationships between biochemical tests, and detecting what are the helpful algorithms and what are not. The patterns that have discovered could be helped in diagnostic problems without need to more tests to help the Iraqi medical physician to take decisions. While, the proposed algorithms will help the researchers in such type of data that did not analyzed previously, because it acquired from the private Iraqi laboratory. Finally, it could be said that the theoretical concept for such type of study contribute in the future for disease diagnostics. The Classification and Regression Trees (CART) algorithm has been noticed as useful in the clinical field, according to its high gained accuracy with seed=7, and tree pruning, reversely, the SVM failed in analysis. Also, the preprocessing phase is a very important part of this kind of dataset investigation due to its high noise, null values, and high complex raw data. The discovered patterns may be helpful in detecting any health case without requiring more tests, since disease patterns could be discovered as future work by physician help. The suggestions for more research on similar dataset types as studying environmental pollution, and how they affect human health. But more details needed, including determining the place of residence to know where pollution lies according to regions in addition to the place of birth. For example, Lung cancer, heart disease and other diseases related to environmental pollution, according to the type of pollution.

# Authors' declaration:

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are mine ours. Besides, the Figures and images, which are not mine ours, have been given the permission for republication attached with the manuscript.
- Ethical Clearance: The project was approved by the local ethical committee in University of Baghdad.

### Authors' contributions statement:

Sarah Sameer Rasheed is a master student in the Department of Computer Science in the College of Science at the University of Baghdad, Baghdad/Iraq. She has a B.Sc. from the University of Baghdad, Baghdad/Iraq.

She is employee in the ministry of the labor and social affairs.

Suhad Faisal Behadili is a professor in the Department of Computer Science in the College of Science at the University of Baghdad. Baghdad/Iraq. She has a Ph.D. from the LITIS at Normandie University - Le Havre/ France. She currently editorial member of the American Journal of Information Science and Technology. She is a program committee member in several international conferences, and a reviewer for IJS and IASET journals. She has published numerous technical papers, undergraduate/Postgraduate teaching, and outreach.

# **References:**

- 1. Behadili SF, Abd MS, Mohammed IK, Al-SAYYID MM. Breast cancer decisive parameters for Iraqi women via data mining techniques. JOCMS. 2019 Apr 19;5(2).
- Nilashi M, Ibrahim O, Dalvi M, Ahmadi H, Shahmoradi L. Accuracy improvement for diabetes disease classification: a case on a public medical dataset. Fuzzy Inf. Eng. 2017 Sep 1;9(3):345-57. DOI: <u>https://doi.org/10.1016/j.fiae.2017.09.006</u>
- Huang Y, McCullagh P, Black N, Harper R. Feature selection and classification model construction on type 2 diabetic patients' data. Artif Intell Med. 2007 Nov 1;41(3):251-62. DOI: 10.1016/j.artmed.2007.072
- 4. Li J, Fu AW, Fahey P. Efficient discovery of risk patterns in medical data. Artif Intell Med. 2009 Jan 1;45(1):77-89. DOI: 10.1136/svn-2017-000101

- Wasan SK, Bhatnagar V, Kaur H. The impact of data mining techniques on medical diagnostics. Data Sci. J. 2006;5:119-26. DOI: http://doi.org/10.2481/dsj.5.119
- Aljumah AA, Ahamad MG, Siddiqui MK. Application of data mining: Diabetes health care in young and old patients. JKSUCI. 2013 Jul1;25(2): 127-36. <u>https://doi.org/10.1016/j.jksuci.2012.10.003</u>
- Salcedo-Bernal A, Villamil-Giraldo MP, Moreno-Barbosa AD. Clinical data analysis: An opportunity to compare machine learning methods. Procedia Comput Sci. 2016 Jan 1;100(100):731-8. DOI: <u>10.1016/j.procs.2016.09.218</u>
- Diwani SA, Yonah ZO. A novel holistic disease prediction tool using best fit data mining techniques. IJCDS. 2017 Mar 1;6(02):63-72. DOI: http://dx.doi.org/10.12785/IJCDS/060202
- 9. Mustafa TK, Abd MS. Proposed approach for analysing general hygiene information using various data mining algorithms. IJS. 2017;58(1B):337-44.
- 10. Crook M. Clinical biochemistry and metabolic medicine. 8th ed. London. CRC Press, 2012. DOI <u>https://doi.org/10.1201/b13295</u>
- Drab K, Daszykowski M. Clustering in analytical chemistry. J AOAC Int. 2014 Jan 1;97(1):29-38. DOI:<u>https://doi.org/10.5740/jaoacint.SGEDrab</u>
- 12. Han J, Kamber M, Pei J. Data mining concepts and techniques. 3rd ed. Elsevier; 2011 Jun 9.
- Müller AC, Guido S. Introduction to machine learning with Python: a guide for data scientists. " O'Reilly Media, Inc."; 2016 Sep 26.
- 14. Li M. Application of CART decision tree combined with PCA algorithm in intrusion detection. In2017 8th IEEE International Conference on Software Engineering and Service Science (ICSESS) 2017 Nov 24 (pp. 38-41). IEEE. DOI:10.1109/ICSESS.2017.8342859

# تقنيات تنقيب البيانات لتحليل مجموعة البيانات البيوكيميائية العراقية

سارة سمير

سهاد فيصل البهادلى

قسم علوم الحاسبات، كلية العلوم، جامعة بغداد، بغداد، العراق.

# الخلاصة:

يهدف هذا البحث إلى تحليل ومحاكاة بيانات تحاليل الكيمياء الحيوية الحقيقية للكشف عن العلاقات فيما بين التحاليل ، وكيف يؤثر كل منها على الأخرين. تم الحصول على البيانات من مختبر الكيمياء الحيوية العراقي الخاص. كذلك فإن هذه البيانات لها أبعاد عديدة ذات معدل مرتفع من القيم الخالية وأعداد كبيرة من المرضى. بعد ذلك ، تم تطبيق العديد من التجارب على هذه البيانات بدءًا بتقنيات غير خاضعة للرقابة مثل التجمعات الهيكلية وك-الوسائل ، ولكن النتائج لم تكن واضحة. ثم تم تنفيذ خطوة المعالجة المسبقة ، لجعل مجموعة البيانات قابلة للتحليل من خلال تقنيات خاضعة للإشراف مثل التحليل التمبيزي الخطي (LDA) ، وشجرة التصنيف والانحدار (CART) ، والانحدار اللوجستي من خلال تقنيات خاضعة للإشراف مثل التحليل التمبيزي الخطي (LDA) ، وشجرة التصنيف والانحدار (CART) ، والانحدار اللوجستي من خلال تقنيات خاضعة للإشراف مثل التحليل التمبيزي الخطي (LDA) ، وشجرة التصنيف والانحدار (CART) ، والانحدار اللوجستي الخوارزميات السنة الخاضعة للإشراف مثل التحليل التمبيزي الخطي (LDA) ، وشجرة التصنيف والانحدار (CART) ، والانحدار الوجستي من خلال تقنيات خاضعة للإشراف مثل التحليل التمبيزي الخطي (ACM) ، وشجرة التصنيف والانحدار الوجستي من خلال تقنيات خاضعة للإشراف مثل التحليل التمبيزي الخطي (ACM) ، وشجرة التصنيف والانحدار الوجستي الحوام البوارزميات السنة الخاضعة للإشراف. من الجدير بالذكر أن خطوات المعالجة المسبقة تتطلب جهودًا ملحوظة للتعامل مع هذا النوع من البيانات ، نظرًا لأن مجموعة البيانات الخالصة بها العديد من القيم الصفرية بنسبة 8.49% ، ثم تصبح 0٪ بعد تحقيق خطوات المعالجة المسبقة. ثم ، من أجل تطبيق خوارزمية CART ، تم افتراض العديد من القيم الصفرية بنسبة 8.49% ، ثم تصبح 0٪ بعد تحقيق خطوات المعالجة المسبقة. ثم من أجل تطبيق خوارزمية حمليات الخاصة بها العديد من القيم الصفرية بنسبة على الاختبار الاختبار الختبار التي تم غم صحق من أجل تطبيق خوارزمية حمليات الخاصة بها العديد من القيم الصفرية بنسبة 3.49% ، ثم تصبح 0٪ بعد تحقيق خطوات المعالجة المسبقة. ثم م من أجل تطبيق خوارزمية حمله من الخالصة بها العديد من الاختبار ات المحددة كفئات. قرار اختبار التم مع بعضها المعراض على أثم م م م من محموعة المرضي ، مما يول نقيما المكنسبة المحمد ترفي م منين و م من تنيزم المحمو م التمي م

الكلمات المفتاحية: الطب الحيوي، شجرة التصنيف والانحدار (CART)، استخراج البيانات، التجمعات الهرمية، ك-الوسائل.